Product Description
Idarubicin is a 4-demethoxy-anthracycline analogue of daunorubicin which, when administered intravenously in combination with cytarabine, has therapeutic efficacy superior to that of standard induction and salvage treatment regimens in acute myelogenous leukaemia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1723369/)
Mechanisms of Action: mTOR Inhibitor,TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Clavis Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Norway, Poland, Portugal, Romania, Serbia, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 2: Hepatocellular Carcinoma|Liver Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IDADOX | P2 |
Recruiting |
Hepatocellular Carcinoma|Liver Cancer |
2025-12-31 |
12% |
2025-01-08 |
Primary Completion Date|Primary Endpoints |
| LIDA-BII | P2 |
Recruiting |
Hepatocellular Carcinoma |
2025-06-18 |
12% |
2025-01-23 |
|
| IDAML | P2 |
Completed |
Acute Myeloid Leukemia |
2025-03-01 |
2025-03-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| QuANTUM-WILD | P3 |
Recruiting |
Leukemia |
2030-06-26 |
68% |
2024-12-06 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| TOT17 | P3 |
Active, not recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2026-09-30 |
27% |
2024-11-27 |
Primary Endpoints|Treatments |
| IntReALL SR 2010 | P3 |
Completed |
Acute Lymphoid Leukemia |
2024-04-25 |
2025-05-06 |
Treatments |
|
| CTR20222667 | P3 |
Recruiting |
Acute Myeloid Leukemia |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |